Compare KITTW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITTW | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 47 | 1300 |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | N/A |
| Metric | KITTW | WGSWW |
|---|---|---|
| Price | $0.05 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.3K | ★ 106.4K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | $0.02 | $0.00 |
| 52 Week High | $0.15 | $0.23 |
| Indicator | KITTW | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 43.08 |
| Support Level | $0.04 | $0.01 |
| Resistance Level | $0.07 | $0.02 |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.56 | 31.01 |
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.